Loading…
RiPP antibiotics: biosynthesis and engineering potential
[Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in e...
Saved in:
Published in: | Current opinion in microbiology 2018-10, Vol.45 (C), p.61-69 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3 |
container_end_page | 69 |
container_issue | C |
container_start_page | 61 |
container_title | Current opinion in microbiology |
container_volume | 45 |
creator | Hudson, Graham A Mitchell, Douglas A |
description | [Display omitted]
The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class. |
doi_str_mv | 10.1016/j.mib.2018.02.010 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6131089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1369527417300826</els_id><sourcerecordid>2013786884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</originalsourceid><addsrcrecordid>eNp9UdFKHDEUDcVSrfYD-iKLT32ZMZlkZhIFoYitglCR9jlkkju7d5lNtkl2wb83y1qpLz6EXLjnnHvuPYR8ZbRmlHXny3qFQ91QJmva1JTRD-SIyV5VlHfioNS8U1Xb9OKQfE5pSSkVqu0-kcNGtZxL0R4R-YgPDzPjMw4YMtp0MStFevJ5AQlT6bgZ-Dl6gIh-PluHDAVsphPycTRTgi8v_zH58-Pm9_Vtdf_r59319_vKtkLkSva2kbxRTnKwdOxHKN6Ms60dx1Y5pQYwXV-e4K1xfT9w5vhgJLemAaCWH5Orve56M6zA2TI9mkmvI65MfNLBoH7b8bjQ87DVHeOMSlUEzvYCIWXUyWIGu7DBe7BZs04JxmQBfXuZEsPfDaSsV5gsTJPxEDZJlxvzXnZSigJle6iNIaUI46sXRvUuFr0s5GFHkZo2usRSOKf_L_HK-JdDAVzuAVBOuUWIO6PgLTiMO58u4Dvyzwj8nvo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013786884</pqid></control><display><type>article</type><title>RiPP antibiotics: biosynthesis and engineering potential</title><source>Elsevier</source><creator>Hudson, Graham A ; Mitchell, Douglas A</creator><creatorcontrib>Hudson, Graham A ; Mitchell, Douglas A</creatorcontrib><description>[Display omitted]
The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</description><identifier>ISSN: 1369-5274</identifier><identifier>EISSN: 1879-0364</identifier><identifier>DOI: 10.1016/j.mib.2018.02.010</identifier><identifier>PMID: 29533845</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - metabolism ; Anti-Bacterial Agents - pharmacology ; Bacteria - drug effects ; Bacteria - genetics ; Bacteria - metabolism ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Biosynthetic Pathways ; Humans ; Peptides - chemistry ; Peptides - metabolism ; Peptides - pharmacology ; Protein Processing, Post-Translational ; Ribosomes - genetics ; Ribosomes - metabolism</subject><ispartof>Current opinion in microbiology, 2018-10, Vol.45 (C), p.61-69</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</citedby><cites>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</cites><orcidid>0000-0002-9564-0953 ; 0000000295640953</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29533845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/1694118$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Hudson, Graham A</creatorcontrib><creatorcontrib>Mitchell, Douglas A</creatorcontrib><title>RiPP antibiotics: biosynthesis and engineering potential</title><title>Current opinion in microbiology</title><addtitle>Curr Opin Microbiol</addtitle><description>[Display omitted]
The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</description><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - metabolism</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - genetics</subject><subject>Bacteria - metabolism</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Biosynthetic Pathways</subject><subject>Humans</subject><subject>Peptides - chemistry</subject><subject>Peptides - metabolism</subject><subject>Peptides - pharmacology</subject><subject>Protein Processing, Post-Translational</subject><subject>Ribosomes - genetics</subject><subject>Ribosomes - metabolism</subject><issn>1369-5274</issn><issn>1879-0364</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UdFKHDEUDcVSrfYD-iKLT32ZMZlkZhIFoYitglCR9jlkkju7d5lNtkl2wb83y1qpLz6EXLjnnHvuPYR8ZbRmlHXny3qFQ91QJmva1JTRD-SIyV5VlHfioNS8U1Xb9OKQfE5pSSkVqu0-kcNGtZxL0R4R-YgPDzPjMw4YMtp0MStFevJ5AQlT6bgZ-Dl6gIh-PluHDAVsphPycTRTgi8v_zH58-Pm9_Vtdf_r59319_vKtkLkSva2kbxRTnKwdOxHKN6Ms60dx1Y5pQYwXV-e4K1xfT9w5vhgJLemAaCWH5Orve56M6zA2TI9mkmvI65MfNLBoH7b8bjQ87DVHeOMSlUEzvYCIWXUyWIGu7DBe7BZs04JxmQBfXuZEsPfDaSsV5gsTJPxEDZJlxvzXnZSigJle6iNIaUI46sXRvUuFr0s5GFHkZo2usRSOKf_L_HK-JdDAVzuAVBOuUWIO6PgLTiMO58u4Dvyzwj8nvo</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Hudson, Graham A</creator><creator>Mitchell, Douglas A</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9564-0953</orcidid><orcidid>https://orcid.org/0000000295640953</orcidid></search><sort><creationdate>20181001</creationdate><title>RiPP antibiotics: biosynthesis and engineering potential</title><author>Hudson, Graham A ; Mitchell, Douglas A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - metabolism</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - genetics</topic><topic>Bacteria - metabolism</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Biosynthetic Pathways</topic><topic>Humans</topic><topic>Peptides - chemistry</topic><topic>Peptides - metabolism</topic><topic>Peptides - pharmacology</topic><topic>Protein Processing, Post-Translational</topic><topic>Ribosomes - genetics</topic><topic>Ribosomes - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hudson, Graham A</creatorcontrib><creatorcontrib>Mitchell, Douglas A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hudson, Graham A</au><au>Mitchell, Douglas A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RiPP antibiotics: biosynthesis and engineering potential</atitle><jtitle>Current opinion in microbiology</jtitle><addtitle>Curr Opin Microbiol</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>45</volume><issue>C</issue><spage>61</spage><epage>69</epage><pages>61-69</pages><issn>1369-5274</issn><eissn>1879-0364</eissn><abstract>[Display omitted]
The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29533845</pmid><doi>10.1016/j.mib.2018.02.010</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9564-0953</orcidid><orcidid>https://orcid.org/0000000295640953</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1369-5274 |
ispartof | Current opinion in microbiology, 2018-10, Vol.45 (C), p.61-69 |
issn | 1369-5274 1879-0364 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6131089 |
source | Elsevier |
subjects | Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - metabolism Anti-Bacterial Agents - pharmacology Bacteria - drug effects Bacteria - genetics Bacteria - metabolism Bacterial Infections - drug therapy Bacterial Infections - microbiology Biosynthetic Pathways Humans Peptides - chemistry Peptides - metabolism Peptides - pharmacology Protein Processing, Post-Translational Ribosomes - genetics Ribosomes - metabolism |
title | RiPP antibiotics: biosynthesis and engineering potential |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RiPP%20antibiotics:%20biosynthesis%20and%20engineering%20potential&rft.jtitle=Current%20opinion%20in%20microbiology&rft.au=Hudson,%20Graham%20A&rft.date=2018-10-01&rft.volume=45&rft.issue=C&rft.spage=61&rft.epage=69&rft.pages=61-69&rft.issn=1369-5274&rft.eissn=1879-0364&rft_id=info:doi/10.1016/j.mib.2018.02.010&rft_dat=%3Cproquest_pubme%3E2013786884%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2013786884&rft_id=info:pmid/29533845&rfr_iscdi=true |